| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | M J Christie | |
| P2860 | cites work | Enhanced opioid efficacy in opioid dependence is caused by an altered signal transduction pathway. | Q44350852 |
| Enhanced Fos expression in glutamic acid decarboxylase immunoreactive neurons of the mouse periaqueductal grey during opioid withdrawal | Q44351355 | ||
| Regulation of RGS proteins by chronic morphine in rat locus coeruleus | Q44373732 | ||
| Involvement of the Lateral Hypothalamic Peptide Orexin in Morphine Dependence and Withdrawal | Q44418957 | ||
| Locus-specific rescue of GluRepsilon1 NMDA receptors in mutant mice identifies the brain regions important for morphine tolerance and dependence. | Q44524204 | ||
| Modulation of GABA release during morphine withdrawal in midbrain neurons in vitro | Q44563662 | ||
| Brain region-specific mechanisms for acute morphine-induced mitogen-activated protein kinase modulation and distinct patterns of activation during analgesic tolerance and locomotor sensitization. | Q44580806 | ||
| Neuronal protein kinase C gamma-dependent proliferation and hypertrophy of spinal cord astrocytes following repeated in vivo administration of morphine | Q44729849 | ||
| Plasticity of reward neurocircuitry and the 'dark side' of drug addiction | Q46177203 | ||
| CREB modulates excitability of nucleus accumbens neurons | Q46395403 | ||
| An essential role for DeltaFosB in the nucleus accumbens in morphine action | Q46896171 | ||
| Contribution of brainstem GABA(A) synaptic transmission to morphine analgesic tolerance | Q46983237 | ||
| Rapid synthesis and synaptic insertion of GluR2 for mGluR-LTD in the ventral tegmental area | Q48093999 | ||
| Total neurochemical lesion of noradrenergic neurons of the locus ceruleus does not alter either naloxone-precipitated or spontaneous opiate withdrawal nor does it influence ability of clonidine to reverse opiate withdrawal. | Q48159688 | ||
| Opioids block long-term potentiation of inhibitory synapses | Q48187662 | ||
| Opioids excite dopamine neurons by hyperpolarization of local interneurons | Q48543154 | ||
| Role of cAMP response element-binding protein in the rat locus ceruleus: regulation of neuronal activity and opiate withdrawal behaviors. | Q48566183 | ||
| A common mechanism mediates long-term changes in synaptic transmission after chronic cocaine and morphine. | Q51576357 | ||
| Should we be reluctant to prescribe opioids for chronic non-malignant pain? | Q53982985 | ||
| Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion | Q59080348 | ||
| Sensitization to repeated morphine injection in the rat: possible involvement of A10 dopamine neurons | Q68996432 | ||
| Increased probability of GABA release during withdrawal from morphine | Q71955013 | ||
| NEURAL MECHANISMS OF ADDICTION: The Role of Reward-Related Learning and Memory | Q22241980 | ||
| Synaptic plasticity and addiction | Q22337221 | ||
| LTP and LTD | Q22337342 | ||
| A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers | Q24530081 | ||
| Protein kinase A-mediated phosphorylation of the beta 2-adrenergic receptor regulates its coupling to Gs and Gi. Demonstration in a reconstituted system | Q28204412 | ||
| mu-Opposing actions of the kappa-opioid receptor | Q28270615 | ||
| Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation | Q28345401 | ||
| ADP-ribosylation factor-dependent phospholipase D2 activation is required for agonist-induced mu-opioid receptor endocytosis | Q28567066 | ||
| Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence | Q28590279 | ||
| AKAP signalling complexes: focal points in space and time | Q29618533 | ||
| The many faces of CREB | Q29622920 | ||
| Addition of a second opioid may improve opioid response in cancer pain: preliminary data | Q30939189 | ||
| Enhanced spinal nociceptin receptor expression develops morphine tolerance and dependence. | Q31454582 | ||
| Threonine 180 is required for G-protein-coupled receptor kinase 3- and beta-arrestin 2-mediated desensitization of the mu-opioid receptor in Xenopus oocytes | Q31520490 | ||
| Opioid receptor signalling mechanisms. | Q33687022 | ||
| Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. | Q33873664 | ||
| Molecular mechanisms and regulation of opioid receptor signaling | Q33932163 | ||
| Single cocaine exposure in vivo induces long-term potentiation in dopamine neurons | Q33949219 | ||
| Desensitization of mu-opioid receptor-evoked potassium currents: initiation at the receptor, expression at the effector | Q34049673 | ||
| Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization | Q34113042 | ||
| Cellular and synaptic adaptations mediating opioid dependence. | Q34127771 | ||
| Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series | Q34244966 | ||
| Opioid receptors | Q34326054 | ||
| Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex | Q34479813 | ||
| Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. | Q34494218 | ||
| Endogenous orphanin FQ/nociceptin is involved in the development of morphine tolerance | Q34510612 | ||
| Role of NK-1 neurotransmission in opioid-induced hyperalgesia | Q34545402 | ||
| GABA transporter currents activated by protein kinase A excite midbrain neurons during opioid withdrawal | Q34554848 | ||
| An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization | Q34580057 | ||
| Regional and cellular mapping of cAMP response element-mediated transcription during naltrexone-precipitated morphine withdrawal. | Q43972763 | ||
| Brain-derived neurotrophic factor is essential for opiate-induced plasticity of noradrenergic neurons. | Q43999190 | ||
| Dopamine transporter-mediated conductances increase excitability of midbrain dopamine neurons. | Q44157335 | ||
| Opioid agonists differentially regulate mu-opioid receptors and trafficking proteins in vivo | Q44219298 | ||
| Rostral ventromedial medulla neurons that project to the spinal cord express multiple opioid receptor phenotypes. | Q44251944 | ||
| Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons | Q44322848 | ||
| Adenylyl cyclase type II activity is regulated by two different mechanisms: implications for acute and chronic opioid exposure | Q44329848 | ||
| Separation of mu-opioid receptor desensitization and internalization: endogenous receptors in primary neuronal cultures. | Q44330114 | ||
| Contingent and non-contingent effects of heroin on mu-opioid receptor-containing ventral tegmental area GABA neurons | Q44331166 | ||
| Opioid receptor endocytosis and activation of MAP kinase pathway | Q44331169 | ||
| Behavioral and electrophysiological evidence for opioid tolerance in adolescent rats | Q44331243 | ||
| Chronic heroin self-administration desensitizes mu opioid receptor-activated G-proteins in specific regions of rat brain. | Q44331908 | ||
| How important is protein kinase C in mu-opioid receptor desensitization and morphine tolerance? | Q44332145 | ||
| Postsynaptic signaling via the [mu]-opioid receptor: responses of dorsal horn neurons to exogenous opioids and noxious stimulation. | Q44333978 | ||
| Prescription drug abuse rises globally | Q44334648 | ||
| Beta-arrestin2 and c-Src regulate the constitutive activity and recycling of mu opioid receptors in dorsal root ganglion neurons. | Q44334988 | ||
| Cholera toxin-A subunit blocks opioid excitatory effects on sensory neuron action potentials indicating mediation by Gs-linked opioid receptors | Q44338609 | ||
| Opioid agonists have different efficacy profiles for G protein activation, rapid desensitization, and endocytosis of mu-opioid receptors | Q44340828 | ||
| Morphine acutely regulates opioid receptor trafficking selectively in dendrites of nucleus accumbens neurons. | Q44341663 | ||
| Cellular mechanisms of opioid tolerance: studies in single brain neurons | Q44342163 | ||
| Mu-opioid receptor desensitization in mature rat neurons: lack of interaction between DAMGO and morphine. | Q44343591 | ||
| Local opioid withdrawal in rat single periaqueductal gray neurons in vitro. | Q44344125 | ||
| Protein kinase C activation enhances morphine-induced rapid desensitization of mu-opioid receptors in mature rat locus ceruleus neurons | Q44346663 | ||
| Induction of delta-opioid receptor function in the midbrain after chronic morphine treatment. | Q44348492 | ||
| A mitogen-activated protein kinase pathway is required for mu-opioid receptor desensitization | Q44348585 | ||
| Morphine-Induced mu-opioid receptor desensitization | Q44349685 | ||
| Increased opioid inhibition of GABA release in nucleus accumbens during morphine withdrawal. | Q44349727 | ||
| Enhanced c-Fos in periaqueductal grey GABAergic neurons during opioid withdrawal | Q44349950 | ||
| IRS2-Akt pathway in midbrain dopamine neurons regulates behavioral and cellular responses to opiates. | Q34586869 | ||
| Opioid tolerance in periaqueductal gray neurons isolated from mice chronically treated with morphine | Q35049134 | ||
| Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling | Q35213474 | ||
| Activation in extended amygdala corresponds to altered hedonic processing during protracted morphine withdrawal | Q35662255 | ||
| Role for GDNF in biochemical and behavioral adaptations to drugs of abuse. | Q35671426 | ||
| Mitogen-activated protein kinases in synaptic plasticity and memory. | Q35803116 | ||
| Desensitization of G protein-coupled receptors and neuronal functions | Q35817048 | ||
| Brain substrates for increased drug seeking during protracted withdrawal | Q35908718 | ||
| Mu-opioid receptor desensitization: is morphine different? | Q35927616 | ||
| Opioids: cellular mechanisms of tolerance and physical dependence | Q36015622 | ||
| Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. | Q36023935 | ||
| Age-dependent opioid escalation in chronic pain patients | Q36141383 | ||
| Sensitization of adenylate cyclase by Galpha i/o-coupled receptors | Q36142386 | ||
| Morphine-activated opioid receptors elude desensitization by beta-arrestin | Q36280218 | ||
| Glia: novel counter-regulators of opioid analgesia | Q36295741 | ||
| Novel pharmacotherapeutic targets for the management of drug addiction | Q36298765 | ||
| Neurobiology of relapse to heroin and cocaine seeking: an update and clinical implications | Q36313598 | ||
| Addiction and its brain science | Q36347915 | ||
| Relapse to alcohol and drug use among individuals diagnosed with co-occurring mental health and substance use disorders: a review | Q36365653 | ||
| The role of opioid receptor phosphorylation and trafficking in adaptations to persistent opioid treatment | Q36506160 | ||
| Role of ERK in cocaine addiction. | Q36644835 | ||
| Drug addiction: pathways to the disease and pathophysiological perspectives | Q36684291 | ||
| Regulatory mechanisms of AMPA receptors in synaptic plasticity | Q36712947 | ||
| Sensing and expressing homeostatic synaptic plasticity. | Q36724238 | ||
| Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location | Q36758556 | ||
| Chronic morphine treatment reduces recovery from opioid desensitization | Q36781613 | ||
| Opioid dependence and addiction during opioid treatment of chronic pain | Q36812289 | ||
| Dynorphin and the pathophysiology of drug addiction | Q36942175 | ||
| Phosphorylation of Galphas influences its association with the micro-opioid receptor and is modulated by long-term morphine exposure | Q40118158 | ||
| Receptor endocytosis counteracts the development of opioid tolerance | Q40505684 | ||
| Carboxyl-terminal splicing of the rat mu opioid receptor modulates agonist-mediated internalization and receptor resensitization. | Q41037609 | ||
| The stimulatory effect of opioids on mitogen-activated protein kinase in Chinese hamster ovary cells transfected to express mu-opioid receptors. | Q41172291 | ||
| Morphine activates opioid receptors without causing their rapid internalization | Q41175884 | ||
| Where is the locus in opioid withdrawal? | Q41468959 | ||
| The involvement of glial cells in the development of morphine tolerance | Q43542087 | ||
| Evaluation of rat ultrasonic vocalizations as predictors of the conditioned aversive effects of drugs. | Q43618061 | ||
| Local opiate withdrawal in locus coeruleus neurons in vitro | Q43626772 | ||
| mu-Opioid receptor downregulation contributes to opioid tolerance in vivo | Q43648934 | ||
| Hippocampal long-term potentiation is reduced by chronic opiate treatment and can be restored by re-exposure to opiates. | Q43907014 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | opioid | Q427523 |
| P304 | page(s) | 384-396 | |
| P577 | publication date | 2008-04-14 | |
| P1433 | published in | British Journal of Pharmacology | Q919631 |
| P1476 | title | Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction | |
| P478 | volume | 154 |
| Q30570686 | A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine |
| Q44340996 | A real-time, fluorescence-based assay for measuring μ-opioid receptor modulation of adenylyl cyclase activity in Chinese hamster ovary cells |
| Q36244665 | Activation of serotonin 5-HT(2C) receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in heroin-treated mice |
| Q33709318 | Acute morphine alters GABAergic transmission in the central amygdala during naloxone-precipitated morphine withdrawal: role of cyclic AMP. |
| Q38193927 | Adherence monitoring with chronic opioid therapy for persistent pain: a biopsychosocial-spiritual approach to mitigate risk |
| Q59800497 | Advances in Achieving Opioid Analgesia Without Side Effects |
| Q39639691 | Agonists at the δ‐opioid receptor modify the binding of µ‐receptor agonists to the µ–δ receptor hetero‐oligomer |
| Q38815838 | An overview of treatment approaches for chronic pain management |
| Q34957285 | Analgesic tone conferred by constitutively active mu opioid receptors in mice lacking β-arrestin 2 |
| Q35589969 | Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human |
| Q92681147 | Anhedonia in chronic pain and prescription opioid misuse |
| Q38259272 | Animal models for opioid addiction drug discovery |
| Q48228161 | Are trans diagnostic models of eating disorders fit for purpose? A consideration of the evidence for food addiction |
| Q37402259 | Association of OPRD1 polymorphisms with heroin dependence in a large case-control series |
| Q38311702 | Beyond traditional pharmacology: new tools and approaches |
| Q37193219 | Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects. |
| Q38046650 | Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence |
| Q37428727 | Capturing adenylyl cyclases as potential drug targets |
| Q38895278 | Cdk5: An Emerging Kinase in Pain Signaling |
| Q34939824 | Change in functional selectivity of morphine with the development of antinociceptive tolerance. |
| Q36043728 | Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo). |
| Q37675344 | Characterization of the Antinociceptive Mechanisms of Khat Extract (Catha edulis) in Mice |
| Q35688547 | Chronic methadone treatment shows a better cost/benefit ratio than chronic morphine in mice |
| Q33936309 | Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction. |
| Q41897800 | Comparison of Duration of Spinal Anesthesia with Lidocaine or Lidocaine plus Epinephrine between Addicts and Non-addicts |
| Q39220347 | Constitutive μ-opioid receptor activity leads to long-term endogenous analgesia and dependence |
| Q28575159 | Correlation of rat cortical Fas-associated death domain (FADD) protein phosphorylation with the severity of spontaneous morphine abstinence syndrome: role of α(2)-adrenoceptors and extracellular signal-regulated kinases |
| Q36407509 | Crucial involvement of actin filaments in celecoxib and morphine analgesia in a model of inflammatory pain |
| Q27693220 | Current research on opioid receptor function |
| Q42076848 | Delta receptors are required for full inhibitory coupling of mu-receptors to voltage-dependent Ca(2+) channels in dorsal root ganglion neurons |
| Q38187199 | Different mechanisms of homologous and heterologous μ-opioid receptor phosphorylation |
| Q39366472 | Differential association of receptor-Gβγ complexes with β-arrestin2 determines recycling bias and potential for tolerance of δ opioid receptor agonists |
| Q38617993 | Differential desensitization observed at multiple effectors of somatic mu opioid receptors underlies sustained agonist-mediated inhibition of proopiomelanocortin neuron activity |
| Q44332812 | Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain |
| Q39754851 | Dopamine D1-like Receptors Regulate Constitutive, μ-Opioid Receptor-Mediated Repression of Use-Dependent Synaptic Plasticity in Dorsal Horn Neurons: More Harm than Good? |
| Q35090837 | Drug-induced sensitization of adenylyl cyclase: assay streamlining and miniaturization for small molecule and siRNA screening applications |
| Q33805049 | ELK1 transcription factor linked to dysregulated striatal mu opioid receptor signaling network and OPRM1 polymorphism in human heroin abusers. |
| Q21132475 | Effect of Iboga alkaloids on µ-opioid receptor-coupled G protein activation |
| Q38250226 | Endogenous analgesia, dependence, and latent pain sensitization |
| Q58598318 | Endogenous pain modulation profiles among individuals with chronic pain: Relation to opioid use |
| Q36914283 | Escalation of cocaine intake with extended access in rats: dysregulated addiction or regulated acquisition? |
| Q35122783 | Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia |
| Q24609658 | Food reward, hyperphagia, and obesity |
| Q55402831 | Functionality versus dimensionality in psychological taxonomies, and a puzzle of emotional valence. |
| Q35921655 | GRK2 protein-mediated transphosphorylation contributes to loss of function of μ-opioid receptors induced by neuropeptide FF (NPFF2) receptors |
| Q28484293 | Global changes in the rat heart proteome induced by prolonged morphine treatment and withdrawal |
| Q41763649 | HIV-1 Tat and morphine have interactive effects on oligodendrocyte survival and morphology |
| Q92642583 | Heterodimerization of Mu Opioid Receptor Protomer with Dopamine D2 Receptor Modulates Agonist-Induced Internalization of Mu Opioid Receptor |
| Q64889813 | History of Alcohol and Opioid Use Impacts on the Long-Term Recovery Trajectories of Methamphetamine-Dependent Patients. |
| Q44332120 | IRAS Modulates Opioid Tolerance and Dependence by Regulating μ Opioid Receptor Trafficking |
| Q38631900 | Iatrogenic Opioid Withdrawal in Critically Ill Patients: A Review of Assessment Tools and Management |
| Q90185275 | Improved efficacy, tolerance, safety and abuse liability profile of the combination CR4056-morphine over morphine alone in rodent models |
| Q88030717 | In vitro and in vivo functional profile characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3-carboxamido)morphinan (NAQ) as a low efficacy mu opioid receptor modulator |
| Q50651446 | Incentives for wellness: tackling issues of effectiveness, biology, scope, and cost shifting. |
| Q36017250 | Inflammatory Pain Promotes Increased Opioid Self-Administration: Role of Dysregulated Ventral Tegmental Area μ Opioid Receptors. |
| Q34242604 | Influence of depressive symptoms on dopaminergic treatment of Parkinson's disease |
| Q37673263 | Insight into pain-inducing and -related gene expression: a challenge for development of novel targeted therapeutic approaches |
| Q43062074 | Insights into the Role of Opioid Receptors in the GI Tract: Experimental Evidence and Therapeutic Relevance. |
| Q57032083 | Insurance Companies Fighting the Peer Review Empire without any Validity: the Case for Addiction and Pain Modalities in the face of an American Drug Epidemic |
| Q24302002 | Interaction of the mu-opioid receptor with GPR177 (Wntless) inhibits Wnt secretion: potential implications for opioid dependence |
| Q26768068 | Interactions of Opioids and HIV Infection in the Pathogenesis of Chronic Pain |
| Q27025236 | Involvement of Mammalian RF-Amide Peptides and Their Receptors in the Modulation of Nociception in Rodents |
| Q27006957 | Kir3 channel signaling complexes: focus on opioid receptor signaling |
| Q36654621 | Ligand-biased activation of extracellular signal-regulated kinase 1/2 leads to differences in opioid induced antinociception and tolerance. |
| Q34154223 | Ligand-directed trafficking of the δ-opioid receptor in vivo: two paths toward analgesic tolerance |
| Q36780862 | Ligand-induced μ opioid receptor internalization in enteric neurons following chronic treatment with the opiate fentanyl |
| Q45063674 | Long-term morphine delivery via slow release morphine pellets or osmotic pumps: Plasma concentration, analgesia, and naloxone-precipitated withdrawal |
| Q37629809 | Loss of μ opioid receptor signaling in nociceptors, but not microglia, abrogates morphine tolerance without disrupting analgesia |
| Q91665539 | Machine learning: assessing neurovascular signals in the prefrontal cortex with non-invasive bimodal electro-optical neuroimaging in opiate addiction |
| Q36025329 | Mechanisms of rapid opioid receptor desensitization, resensitization and tolerance in brain neurons |
| Q38066970 | Medical management of acute pain in patients with chronic pain |
| Q26777352 | Milk metabolites and neurodegeneration: Is there crosstalk? |
| Q90301890 | Mindfulness-oriented recovery enhancement reduces opioid misuse risk via analgesic and positive psychological mechanisms: A randomized controlled trial |
| Q90732131 | Mitogen-Activated Protein Kinase Signaling Mediates Morphine Induced-Delayed Hyperalgesia |
| Q37410471 | Modulation of opioid receptor function by protein-protein interactions |
| Q38248063 | Molecular physiology of enteric opioid receptors |
| Q30413204 | Morphine induces redox-based changes in global DNA methylation and retrotransposon transcription by inhibition of excitatory amino acid transporter type 3-mediated cysteine uptake |
| Q44336809 | Morphine withdrawal enhances constitutive μ-opioid receptor activity in the ventral tegmental area. |
| Q37592198 | Morphine-induced trafficking of a mu-opioid receptor interacting protein in rat locus coeruleus neurons |
| Q52662103 | Morphine-potentiated cognitive deficits correlate to suppressed hippocampal iNOS RNA expression and an absent type 1 interferon response in LP-BM5 murine AIDS. |
| Q36163576 | Multiple inhibitory G-protein-coupled receptors resist acute desensitization in the presynaptic but not postsynaptic compartments of neurons |
| Q34285878 | NADPH-oxidase 2 activation promotes opioid-induced antinociceptive tolerance in mice |
| Q34023781 | Negotiating the Relationship Between Addiction, Ethics, and Brain Science |
| Q35050888 | Neuroadaptation of GABAergic transmission in the central amygdala during chronic morphine treatment |
| Q37471551 | Neurochemistry underlying relapse to opiate seeking behaviour |
| Q26799409 | Neuropathic Pain due to Small Fiber Neuropathy in Aging: Current Management and Future Prospects |
| Q26991923 | Neurotrophins in the ventral tegmental area: Role in social stress, mood disorders and drug abuse |
| Q39883445 | Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor |
| Q37314261 | Newer approaches to opioid detoxification |
| Q41887362 | Noni (Morinda citrifolia L.) fruit extract attenuates the rewarding effect of heroin in conditioned place preference but not withdrawal in rodents. |
| Q35956747 | Opiate antagonist prevents μ- and δ-opiate receptor dimerization to facilitate ability of agonist to control ethanol-altered natural killer cell functions and mammary tumor growth |
| Q36201412 | Opiate drug use and the pathophysiology of neuroAIDS. |
| Q43061639 | Opiates and Plasticity in the Ventral Tegmental Area |
| Q93081359 | Opioid Addiction, Genetic Susceptibility, and Medical Treatments: A Review |
| Q35090939 | Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice |
| Q39027943 | Opioid receptor gene expression in human neuroblastoma SH-SY5Y cells following tapentadol exposure |
| Q34305249 | Opioid rotation in clinical practice |
| Q35247464 | Opioid use affects antioxidant activity and purine metabolism: preliminary results |
| Q27021477 | Opioid-induced central immune signaling: implications for opioid analgesia |
| Q37483897 | Pain treatment with opioids : achieving the minimal effective and the minimal interacting dose |
| Q90224955 | Performance of Local Anesthesia with Lidocaine among Opium Addicts and Non-Addicts; a Case Control Study |
| Q34242078 | Pharmacotherapeutic approach to the treatment of addiction: persistent challenges |
| Q36377051 | Prior exposure to repeated morphine potentiates mechanical allodynia induced by peripheral inflammation and neuropathy |
| Q28481707 | Proteomic analysis of PKCγ-related proteins in the spinal cord of morphine-tolerant rats |
| Q33960685 | Rationally designed multitarget agents against inflammation and pain |
| Q41891627 | Recovery from mu-opioid receptor desensitization after chronic treatment with morphine and methadone |
| Q34999412 | Redox-based epigenetic status in drug addiction: a potential contributor to gene priming and a mechanistic rationale for metabolic intervention |
| Q34518254 | Regional expression of extracellular signal-regulated kinase 1 and 2 mRNA in a morphine-induced conditioned place preference model |
| Q37887853 | Regulation of opioid receptor signalling: implications for the development of analgesic tolerance |
| Q36591603 | Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. |
| Q47146266 | Review of the potential health impact of β-casomorphins and related peptides |
| Q37589704 | Role of protein kinase C in functional selectivity for desensitization at the mu-opioid receptor: from pharmacological curiosity to therapeutic potential |
| Q47711187 | Role of the guanine nucleotide binding protein, Gαo, in the development of morphine tolerance and dependence |
| Q27011348 | Roles of the ubiquitin proteasome system in the effects of drugs of abuse |
| Q37352118 | Sex differences in opioid analgesia and addiction: interactions among opioid receptors and estrogen receptors |
| Q36340921 | Short-term pre- and post-operative stress prolongs incision-induced pain hypersensitivity without changing basal pain perception |
| Q38013181 | Spinal mechanisms of pain and analgesia |
| Q34926300 | Stabilization of morphine tolerance with long-term dosing: association with selective upregulation of mu-opioid receptor splice variant mRNAs |
| Q35747694 | Structural Determinants for the Binding of Morphinan Agonists to the μ-Opioid Receptor |
| Q37310339 | T394A Mutation at the μ Opioid Receptor Blocks Opioid Tolerance and Increases Vulnerability to Heroin Self-Administration in Mice |
| Q92644109 | The Emerging Perspective of Morphine Tolerance: MicroRNAs |
| Q93068295 | The Neuro-Psychological Axis of Smoking-Associated Cancer |
| Q89532732 | The changing opioid crisis: development, challenges and opportunities |
| Q35190567 | The effect of the anabolic steroid, nandrolone, in conditioned place preference and D1 dopamine receptor expression in adolescent and adult mice |
| Q37753286 | The role of functional postsynaptic NMDA receptors in the central nucleus of the amygdala in opioid dependence |
| Q35123770 | Tolerance effects of non-steroidal anti-inflammatory drugs microinjected into central amygdala, periaqueductal grey, and nucleus raphe: Possible cellular mechanism. |
| Q34359955 | Tolerance to the Antinociceptive Effect of Morphine in the Absence of Short-Term Presynaptic Desensitization in Rat Periaqueductal Gray Neurons |
| Q26865714 | Traditional Chinese and Indian medicine in the treatment of opioid-dependence: a review |
| Q33896673 | Ultrastructural relationship between N-methyl-D-aspartate-NR1 receptor subunit and mu-opioid receptor in the mouse central nucleus of the amygdala |
| Q57466905 | Why mu-opioid agonists have less analgesic efficacy in neuropathic pain? |
| Q39678425 | beta-Arrestin 2-mediated heterologous desensitization of IGF-IR by prolonged exposure of SH-SY5Y neuroblastoma cells to a mu opioid agonist |
| Q28081540 | mTOR, a new potential target for chronic pain and opioid-induced tolerance and hyperalgesia |
| Q34939769 | β-Arrestin-2 knockout prevents development of cellular μ-opioid receptor tolerance but does not affect opioid-withdrawal-related adaptations in single PAG neurons. |
| Q34939720 | μ-Opioid receptor activation and noradrenaline transport inhibition by tapentadol in rat single locus coeruleus neurons |
| Q34310081 | μ-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization |
Search more.